What Is Dostarlimab, the Drug Used in ‘Unprecedented' Cancer Trial?

Österreich Nachrichten Nachrichten

What Is Dostarlimab, the Drug Used in ‘Unprecedented' Cancer Trial?
Österreich Neuesten Nachrichten,Österreich Schlagzeilen
  • 📰 NBCNewYork
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 63%

A newly disclosed cancer study had 'unprecedented' and 'unheard-of' results, and now all eyes are on dostarlimab, the GlaxoSmithKline drug used to achieve complete remission in the trial.

The term became more widely known in the last two years as a variety of monoclonal antibodies came out to treat COVID-19.

Dostarlimab is specifically designed to block a particular protein involved in cancer cells called PD-1. In the Memorial Sloan Kettering trial with rectal cancer, all of the patients' tumors also had a feature known as mismatch repair deficiency.Cells that have mutations that keep them from fixing mistakes when DNA is copied are said to have"mismatch repair deficiency."Copyright NBC New York

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

NBCNewYork /  🏆 270. in US

Österreich Neuesten Nachrichten, Österreich Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Cancer research: Amgen drug extends survival in some inoperable colon cancersCancer research: Amgen drug extends survival in some inoperable colon cancersThe following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Weiterlesen »

Small Cancer Trial Delivers ‘Unheard-of' Result: Complete Remission for EveryoneSmall Cancer Trial Delivers ‘Unheard-of' Result: Complete Remission for EveryoneA small NYC-led cancer trial has achieved a result reportedly never before seen – the total remission of cancer in all of its patients. To be sure, the trial — led by doctors at Memorial Sloan Kettering and backed by drug maker GlaxoSmithKline — has only completed treatment of 12 patients, with a specific cancer in its early stages and…
Weiterlesen »

Breast cancer drug shows promise, opens new treatment possibilities to thousands of patientsBreast cancer drug shows promise, opens new treatment possibilities to thousands of patientsFor the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.
Weiterlesen »

Researchers: Breast Cancer Drug Could Help More PatientsResearchers: Breast Cancer Drug Could Help More PatientsDoctors are reporting a new gain in breast cancer treatment. Some HER2 negative breast cancers are actually “HER2 low” and can benefit from a drug targeting the HER2 protein.
Weiterlesen »

Researchers: Breast cancer drug could help more patientsResearchers: Breast cancer drug could help more patientsDoctors are reporting a new gain in breast cancer treatment.
Weiterlesen »

Small Rectal Cancer Study Has Remission in Every PatientSmall Rectal Cancer Study Has Remission in Every PatientA small clinical trial with 12 rectal cancer patients found remission in 100% of them, according to a new paper published in The New England Journal of Medicine.
Weiterlesen »



Render Time: 2025-04-02 05:07:51